Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Empowerment comes with a second opinion. After a second opinion appointment at Karmanos Cancer Institute, patients can decide ...

Explore the Global Prostate Care Market's growth, projected to reach USD 69.91 billion by 2031, driven by demographic shifts, tech advances, and the rising incidence of prostate conditions. Key ...

In Malaysia, prostate cancer has been the third-most common type of cancer among men since 2012, doctors caution.

Androgen deprivation therapy is a lifesaving therapy used by thousands of men each year, but some patients are warning of ...

Kenya’s fight against cancer has entered a new phase, driven by technological breakthroughs that promise to transform diagnosis, treatment, and survival rates.

During a live event, Jahan Aghalar, MD, discussed key NCCN-recommended oral therapies and landmark trials for metastatic ...

New research in the July 2025 issue of JNCCN-Journal of the National Comprehensive Cancer Network finds that for people diagnosed with nonmetastatic low-risk prostate cancer later in life, and treated ...

An expert discusses how CT scans and bone scans remain the standard imaging approach for most patients with metastatic castration-resistant prostate cancer (mCRPC), whereas prostate-specific membrane ...

The tissue damage and anatomical distortion caused by primary prostate cancer treatment are major challenges for surgeons performing salvage surgery.

Men with non-metastatic forms are likely to live 'for many years' after diagnosis when active surveillance and other NCCN ...

ArteraAI Prostate analyzes digital pathology images of a prostate cancer biopsy slide to help clinicians predict long-term outcomes.